Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&Jâ€™s Imbruvica, Astellas and Pfizerâ€™s Xtandi, Biogenâ€™s Tysabri, Gileadâ€™s HIV franchise, Merckâ€™s Januvia, Novartisâ€™ Promacta, and Vertexâ€™s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.